DANONE (BSN.DE) Stock Fundamental Analysis
Europe - FRA:BSN - FR0000120644 - Common Stock
79.3 EUR
+0.34 (+0.43%)
Taking everything into account, BSN scores 5 out of 10 in our fundamental rating. BSN was compared to 57 industry peers in the Food Products industry. BSN scores excellent on profitability, but there are some minor concerns on its financial health. While showing a medium growth rate, BSN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year BSN was profitable.
BSN had a positive operating cash flow in the past year.
In the past 5 years BSN has always been profitable.
In the past 5 years BSN always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of BSN (4.20%) is better than 63.16% of its industry peers.
BSN has a Return On Equity of 11.59%. This is in the better half of the industry: BSN outperforms 64.91% of its industry peers.
BSN has a Return On Invested Capital of 6.83%. This is in the better half of the industry: BSN outperforms 63.16% of its industry peers.
BSN had an Average Return On Invested Capital over the past 3 years of 6.38%. This is in line with the industry average of 6.48%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
BSN has a better Profit Margin (6.72%) than 73.68% of its industry peers.
BSN's Profit Margin has been stable in the last couple of years.
BSN has a Operating Margin of 13.25%. This is amongst the best in the industry. BSN outperforms 80.70% of its industry peers.
In the last couple of years the Operating Margin of BSN has declined.
BSN's Gross Margin of 50.47% is fine compared to the rest of the industry. BSN outperforms 78.95% of its industry peers.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BSN is creating some value.
Compared to 1 year ago, BSN has more shares outstanding
BSN has less shares outstanding than it did 5 years ago.
BSN has a better debt/assets ratio than last year.
2.2 Solvency
BSN has an Altman-Z score of 2.58. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
BSN's Altman-Z score of 2.58 is fine compared to the rest of the industry. BSN outperforms 66.67% of its industry peers.
The Debt to FCF ratio of BSN is 5.07, which is a neutral value as it means it would take BSN, 5.07 years of fcf income to pay off all of its debts.
BSN has a better Debt to FCF ratio (5.07) than 71.93% of its industry peers.
A Debt/Equity ratio of 0.83 indicates that BSN is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.83, BSN is not doing good in the industry: 68.42% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.58 |
ROIC/WACC1.04
WACC6.54%
2.3 Liquidity
BSN has a Current Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.95, BSN is doing worse than 73.68% of the companies in the same industry.
A Quick Ratio of 0.78 indicates that BSN may have some problems paying its short term obligations.
BSN has a Quick ratio (0.78) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.47% over the past year.
The Earnings Per Share has been decreasing by -1.17% on average over the past years.
Looking at the last year, BSN shows a small growth in Revenue. The Revenue has grown by 0.54% in the last year.
Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
The Earnings Per Share is expected to grow by 6.39% on average over the next years.
BSN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.15% yearly.
EPS Next Y8%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
EPS Next 5Y6.39%
Revenue Next Year0.68%
Revenue Next 2Y1.86%
Revenue Next 3Y2.53%
Revenue Next 5Y3.15%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 21.20, which indicates a rather expensive current valuation of BSN.
BSN's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 26.34. BSN is around the same levels.
With a Price/Forward Earnings ratio of 18.96, BSN is valued on the expensive side.
BSN's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. BSN is more expensive than 63.16% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.43, BSN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.2 | ||
| Fwd PE | 18.96 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSN is on the same level as its industry peers.
BSN's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.83 | ||
| EV/EBITDA | 11.38 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.65
PEG (5Y)N/A
EPS Next 2Y7.34%
EPS Next 3Y7.61%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.78%, BSN has a reasonable but not impressive dividend return.
BSN's Dividend Yield is a higher than the industry average which is at 3.39.
BSN's Dividend Yield is comparable with the S&P500 average which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.78% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
74.99% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP74.99%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
FRA:BSN (11/12/2025, 7:00:00 PM)
79.3
+0.34 (+0.43%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners55.49%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap54.03B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts74.84
Price Target79.17 (-0.16%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.78% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.65%
PT rev (3m)2.51%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.33%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-0.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.2 | ||
| Fwd PE | 18.96 | ||
| P/S | 1.98 | ||
| P/FCF | 18.83 | ||
| P/OCF | 14.05 | ||
| P/B | 3.41 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.38 |
EPS(TTM)3.74
EY4.72%
EPS(NY)4.18
Fwd EY5.27%
FCF(TTM)4.21
FCFY5.31%
OCF(TTM)5.64
OCFY7.12%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.65
PEG (5Y)N/A
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.58 |
F-Score8
WACC6.54%
ROIC/WACC1.04
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y8%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
EPS Next 5Y6.39%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.68%
Revenue Next 2Y1.86%
Revenue Next 3Y2.53%
Revenue Next 5Y3.15%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.38%
EBIT Next 3Y14.38%
EBIT Next 5Y10.92%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status of DANONE (BSN.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of DANONE (BSN.DE) stock?
The Price/Earnings (PE) ratio for DANONE (BSN.DE) is 21.2 and the Price/Book (PB) ratio is 3.41.
Can you provide the expected EPS growth for BSN stock?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 8% in the next year.